

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1626KAS

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\* \* \* \* \* Welcome to STN International \* \* \* \* \*

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America  
NEWS 2 "Ask CAS" for self-help around the clock  
NEWS 3 FEB 28 PATDPAFULL - New display fields provide for legal status  
data from INPADOC  
NEWS 4 FEB 28 BABS - Current-awareness alerts (SDIs) available  
NEWS 5 MAR 02 GBFULL: New full-text patent database on STN  
NEWS 6 MAR 03 REGISTRY/ZREGISTRY - Sequence annotations enhanced  
NEWS 7 MAR 03 MEDLINE file segment of TOXCENTER reloaded  
NEWS 8 MAR 22 KOREAPAT now updated monthly; patent information enhanced  
NEWS 9 MAR 22 Original IDE display format returns to REGISTRY/ZREGISTRY  
NEWS 10 MAR 22 PATDPASPC - New patent database available  
NEWS 11 MAR 22 REGISTRY/ZREGISTRY enhanced with experimental property tags  
NEWS 12 APR 04 EPFULL enhanced with additional patent information and new  
fields  
NEWS 13 APR 04 EMBASE - Database reloaded and enhanced  
NEWS 14 APR 18 New CAS Information Use Policies available online  
NEWS 15 APR 25 Patent searching, including current-awareness alerts (SDIs),  
based on application date in CA/CAPLUS and USPATFULL/USPAT2  
may be affected by a change in filing date for U.S.  
applications.  
NEWS 16 APR 28 Improved searching of U.S. Patent Classifications for  
U.S. patent records in CA/CAPLUS  
NEWS 17 MAY 23 GBFULL enhanced with patent drawing images  
NEWS 18 MAY 23 REGISTRY has been enhanced with source information from  
CHEMCATS  
NEWS 19 JUN 06 The Analysis Edition of STN Express with Discover!  
(Version 8.0 for Windows) now available  
NEWS 20 JUN 13 RUSSIAPAT: New full-text patent database on STN  
NEWS 21 JUN 13 FRFULL enhanced with patent drawing images  
NEWS 22 JUN 27 MARPAT displays enhanced with expanded G-group definitions  
and text labels  
NEWS 23 JUL 01 MEDICONF removed from STN  
NEWS 24 JUL 07 STN Patent Forums to be held in July 2005  
NEWS 25 JUL 13 SCISEARCH reloaded  
NEWS 26 JUL 20 Powerful new interactive analysis and visualization software,  
STN AnaVist, now available  
  
NEWS EXPRESS JUNE 13 CURRENT WINDOWS VERSION IS V8.0, CURRENT  
MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),  
AND CURRENT DISCOVER FILE IS DATED 13 JUNE 2005  
  
NEWS HOURS STN Operating Hours Plus Help Desk Availability  
NEWS INTER General Internet Information

10772721

08/05/05

NEWS LOGIN Welcome Banner and News Items  
NEWS PHONE Direct Dial and Telecommunication Network Access to STN  
NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

\* \* \* \* \* STN Columbus \* \* \* \* \*

FILE 'HOME' ENTERED AT 16:16:35 ON 07 AUG 2005

=> file reg

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.21

0.21

FILE 'REGISTRY' ENTERED AT 16:16:47 ON 07 AUG 2005

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2005 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 5 AUG 2005 HIGHEST RN 858648-31-4

DICTIONARY FILE UPDATES: 5 AUG 2005 HIGHEST RN 858648-31-4

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 18, 2005

Please note that search-term pricing does apply when conducting SmartSELECT searches.


\*\*\*\*\*  
\*  
\* The CA roles and document type information have been removed from \*  
\* the IDE default display format and the ED field has been added, \*  
\* effective March 20, 2005. A new display format, IDERL, is now \*  
\* available and contains the CA role and document type information. \*  
\*  
\*\*\*\*\*

Structure search iteration limits have been increased. See HELP SLIMITS for details.

Experimental and calculated property data are now available. For more information enter HELP PROP at an arrow prompt in the file or refer to the file summary sheet on the web at:  
<http://www.cas.org/ONLINE/DBSS/registryss.html>

=>

Uploading C:\Program Files\Stnexp\Queries\10772721.str



chain nodes :

10 17 18 19

ring nodes :

1 2 3 4 5 6 7 8 9 11 12 13 14 20 21 22 23 24 25

chain bonds :

2-10 8-17 17-18 17-19 18-20

ring bonds :

1-2 1-5 1-6 1-9 2-3 3-4 3-11 4-5 4-14 6-7 7-8 8-9 11-12 12-13 13-14  
20-21 20-25 21-22 22-23 23-24 24-25

exact/norm bonds :

1-2 1-5 1-6 1-9 2-3 2-10 3-4 3-11 4-5 4-14 6-7 7-8 8-9 11-12 12-13  
13-14 17-18 17-19 18-20

exact bonds :

8-17

normalized bonds :

20-21 20-25 21-22 22-23 23-24 24-25

isolated ring systems :

containing 20 :

Match level :


1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:CLASS  
11:Atom 12:Atom 13:Atom 14:Atom 17:CLASS 18:CLASS 19:CLASS 20:Atom 21:Atom  
22:Atom 23:Atom 24:Atom 25:Atom

L1 STRUCTURE UPLOADED

=> d

L1 HAS NO ANSWERS

L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> s l1

SAMPLE SEARCH INITIATED 16:17:13 FILE 'REGISTRY'  
 SAMPLE SCREEN SEARCH COMPLETED - 27 TO ITERATE

100.0% PROCESSED 27 ITERATIONS 14 ANSWERS  
 SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\*  
 BATCH \*\*COMPLETE\*\*  
 PROJECTED ITERATIONS: 229 TO 851  
 PROJECTED ANSWERS: 56 TO 504

L2 14 SEA SSS SAM L1

=> s l1 full

FULL SEARCH INITIATED 16:17:20 FILE 'REGISTRY'  
 FULL SCREEN SEARCH COMPLETED - 418 TO ITERATE

100.0% PROCESSED 418 ITERATIONS 229 ANSWERS  
 SEARCH TIME: 00.00.01

L3 229 SEA SSS FUL L1

=> file caplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	161.76	161.97

FILE 'CAPLUS' ENTERED AT 16:17:45 ON 07 AUG 2005  
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
 COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching

databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 7 Aug 2005 VOL 143 ISS 7  
FILE LAST UPDATED: 5 Aug 2005 (20050805/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l3

L4 7 L3

=> d ibib abs hitstr tot

10772721

08/05/05

L4 ANSWER 1 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2004:158440 CAPLUS

DOCUMENT NUMBER: 140:354323

TITLE: Characterization of the Binding Site for Inhibitors of the HPV11 E1-E2 Protein Interaction on the E2 Transactivation Domain by Photoaffinity Labeling and Mass Spectrometry

AUTHOR(S): Davidson, Walter; McGibbon, Graham A.; White, Peter W.; Yoakim, Christiane; Hopkins, Jerry L.; Guse, Ingrid; Hamblly, David M.; Frago, Lee; Ogilvie, William W.; Lavalles, Pierre; Archambault, Jacques

CORPORATE SOURCE: Research and Development, Boehringer Ingelheim (Canada) Ltd., Laval, QC, H7S 2G5, Can.

SOURCE: Analytical Chemistry (2004), 76(7), 2095-2102

CODEN: ANCHAM; ISSN: 0003-2700

PUBLISHER: American Chemical Society

DOCUMENT TYPE: Journal

LANGUAGE: English

AB An indandione-containing class of inhibitors abrogates DNA replication of human papillomavirus (HPV) types 6 and 11 by binding reversibly to the transactivation domain (TAD) of the viral E2 protein and inhibiting its interaction with the viral E1 helicase. To locate the binding site of this class of protein-protein interaction inhibitors, a benzophenone derivative was used to generate an irreversibly labeled E2-TAD polypeptide. The single site of covalent modification of the E2-TAD was identified by proteolytic digestions using trypsin, LysC, and V8 proteases and characterization of the resulting peptides by LC-MS procedures. Through this methodol., the benzophenone attachment point was located at the terminal Me of residue Met101. Evidence further pinpointed the site of photoaffinity attachment to the terminal carbon atom, which is significant in providing a definitive example of the ability to locate photoinduced crosslinking to a polypeptide with atomic resolution using solely mass spectrometric detection. The location of the inhibitor binding site vis-a-vis the Glu39 and Glu100 residues sensitive to mutation for HPV 11 E2-TAD is discussed in relation to the crystal structure of the E2-TAD from the related HPV type 16.

IT 680194-88-1

RL: ARU (Analytical role, unclassified); BUU (Biological use, unclassified); ANST (Analytical study); BIOL (Biological study); USES (Uses)

(binding site for inhibitors of HPV11 E1-E2 protein interaction on E2 transactivation domain by photoaffinity labeling and mass spectrometry)


RN 680194-88-1 CAPLUS

CN Spiro[furan-2(3H),2'-(2H)indene]-3-carboxylic acid, 4-[[[4-benzoylphenyl]amino]carbonyl]-5-(3,4-dichlorophenyl)-1',3',4,5-tetrahydro-1',3'-dioxo-, monosodium salt, (3R,4S,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

L4 ANSWER 1 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN

(Continued)



REFERENCE COUNT:

31

THERE ARE 31 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2004:153611 CAPLUS

DOCUMENT NUMBER: 140:357234

TITLE: A series of heterocyclic inhibitors of phenylalanyl-tRNA synthetases with antibacterial activity

AUTHOR(S): Yu, Xiang Y.; Finn, John; Hill, Jason M.; Wang, Zhong G.; Keith, Dennis; Silverman, Jared; Oliver, N.

CORPORATE SOURCE: Department of Medicinal Chemistry, Cubist Pharmaceuticals, Inc., Cambridge, MA, 02139, USA

SOURCE: Bioorganic & Medicinal Chemistry Letters (2004), 14(5), 1343-1346

CODEN: BMCLE8; ISSN: 0960-894X

PUBLISHER: Elsevier Science B.V.

DOCUMENT TYPE: Journal

LANGUAGE: English

AB A series of benzodioxatricycloundecanes was synthesized and evaluated for their ability to inhibit phenylalanyl-tRNA synthetases and act as antibacterial agents. Several analogs have good antibacterial activity against Staphylococcus aureus.

IT 682749-39-9P 682749-46-8P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

(preparation of benzodioxatricycloundecanes as phenylalanyl-tRNA synthetases

with antibacterial activity)


RN 682749-39-9 CAPLUS

CN Puro[2,3-c]indeno[1,2-b]furan-3-carboxamide, N-(3,4-dichlorophenyl)-2,3,3a,4,5a,10-hexahydro-4,10-dioxo-2-phenyl-, (2R,3R,3aS,5aS,10aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

L4 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN


(Continued)



REFERENCE COUNT:

6

THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT




RN 682749-46-8 CAPLUS


CN Spiro[furan-2(3H),2'-(2H)indene]-3-carboxylic acid, 4-[[[3,4-dichlorophenyl]amino]carbonyl]-1',3',4,5-tetrahydro-1',3'-dioxo-5-phenyl-, (3R,4S,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

L4 ANSWER 3 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN  
 ACCESSION NUMBER: 2004:124707 CAPLUS  
 DOCUMENT NUMBER: 140:352268  
 TITLE: Crystal Structure of the E2 Transactivation Domain of Human Papillomavirus Type 11 Bound to a Protein Interaction Inhibitor  
 AUTHOR(S): Wang, Yong; Coulombe, Rene; Cameron, Dale R.; Thauvette, Louise; Massariol, Marie-Josée; Amon, Lynn M.; Fink, Dominique; Titolo, Steve; Welchner, Ewald; Yoakim, Christiane; Archambault, Jacques; White, Peter V.  
 CORPORATE SOURCE: Department of Biological Sciences and Department of Chemistry, Boehringer Ingelheim Ltd., Laval, QC, H7S 2G5, Can.  
 SOURCE: Journal of Biological Chemistry (2004), 279(8), 6976-6985  
 CODEN: JBCHA3; ISSN: 0021-9258  
 PUBLISHER: American Society for Biochemistry and Molecular Biology  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English  
 AB Interaction between the E2 protein and E1 helicase of human papillomaviruses (HPVs) is essential for the initiation of viral DNA replication. We recently described a series of small mols. that bind to the N-terminal transactivation domain (TAD) of HPV type 11 E2 and inhibits its interaction with E1 in vitro and in cellular assays. Here we report the crystal structures of both the HPV11 TAD and of a complex between this domain and an inhibitor, at 2.5- and 2.4-Å resolution, resp. The HPV11 TAD structure is very similar to that of the analogous domain of HPV16. Inhibitor binding caused no significant alteration of the protein backbone, but movements of several amino acid side chains at the binding site, in particular those of Tyr-19, His-32, Leu-94, and Glu-100, resulted in the formation of a deep hydrophobic pocket that accommodates the indandione moiety of the inhibitor. Mutational anal. provides functional evidence for specific interactions between Tyr-19 and E1 and between His-32 and the inhibitor. A second inhibitor mol. is also present at the binding pocket. Although evidence is presented that this second mol. makes only weak interactions with the protein and is likely an artifact of crystallization, its presence defines addnl. regions of the binding pocket that could be exploited to design more potent inhibitors.  
 IT 681294-54-2  
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (structural and biochem. anal. address mol. basis of indandione inhibitor disruption of binding between HPV11 E2 protein transactivation domain and E1 helicase)  
 RN 681294-54-2 CAPLUS  
 CN Spiro[furan-2(3H),2'-(2H)indene]-3-carboxylic acid, 5-(3,4-dibromophenyl)-1',3',4,5-tetrahydro-5'-methyl-4-[[[4-(4-morpholinyl)phenyl]amino]carbonyl]-1'-1',3'-dioxo-, (2R,3R,4S,5R)- (9CI) (CA INDEX NAME)  
 Absolute stereochemistry.




IT 681294-53-1D, complexes with E2 protein  
 RL: PRP (Properties) (structural and biochem. anal. address mol. basis of indandione inhibitor disruption of binding between HPV11 E2 protein transactivation domain and E1 helicase)  
 RN 681294-53-1 CAPLUS  
 CN Spiro[furan-2(3H),2'-(2H)indene]-3-carboxylic acid, 5-(3,4-dichlorophenyl)-1',3',4,5-tetrahydro-5'-methyl-1',3'-dioxo-4-[[[4-(1,2,3-thiadiazol-5-yl)phenyl]amino]carbonyl]-, (2R,3R,4S,5R)- (9CI) (CA INDEX NAME)  
 Absolute stereochemistry.



L4 ANSWER 3 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)  
 REFERENCE COUNT: 49 THERE ARE 49 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L4 ANSWER 4 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN  
 ACCESSION NUMBER: 2003:891609 CAPLUS  
 DOCUMENT NUMBER: 140:104529  
 TITLE: Structure elucidation of the first inhibitors of human papillomavirus type 11 E1-E2 protein-protein interaction  
 AUTHOR(S): Yoakim, Christiane; Goudreau, Nathalie; McGibbon, Graham A.; O'Meara, Jeff; White, Peter W.; Ogilvie, William W.  
 CORPORATE SOURCE: Research & Development, Boehringer Ingelheim (Canada) Ltd., Laval, QC, H7S 2G5, Can.  
 SOURCE: Helvetica Chimica Acta (2003), 86(10), 3427-3444  
 CODEN: HCACAV; ISSN: 0018-019X  
 PUBLISHER: Verlag Helvetica Chimica Acta  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English  
 AB A novel series of inhibitors of the HPV11 E1-E2 protein-protein interaction was identified. These inhibitors, which were discovered as a result of high-throughput screening, feature an indandione system spirofused onto an appropriately substituted THF ring. Early stability studies indicated, surprisingly, that this particular series of compds. were readily converted, in binding assay buffer, to the corresponding carboxylates. NMR and mass spectrometry techniques were used to elucidate the structures of these products and the mechanism by which they are produced.  
 IT 439122-86-8P  
 RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation) (structure elucidation of the first inhibitors of human papillomavirus type 11 E1-E2 protein-protein interaction)  
 RN 439122-86-8 CAPLUS  
 CN Spiro[furan-2(3H),2'-(2H)indene]-3-carboxylic acid, 5-(4-chlorophenyl)-1',3',4,5-tetrahydro-1',3'-dioxo-4-[(phenylamino)carbonyl]-, monosodium salt, (3R,4S,5R)-rel- (9CI) (CA INDEX NAME)  
 Relative stereochemistry.



IT 439122-96-0P 647037-99-8P  
 RL: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation) (structure elucidation of the first inhibitors of human papillomavirus type 11 E1-E2 protein-protein interaction)  
 RN 439122-96-0 CAPLUS  
 CN Spiro[furan-2(3H),2'-(2H)indene]-3-carboxylic acid, 4-[[[4-(acetylphenyl)amino]carbonyl]-5-(3,4-dichlorophenyl)-1',3',4,5-tetrahydro-

L4 ANSWER 4 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)  
1',3'-dioxo-, monosodium salt, (3R,4S,5R)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



● Na

RN 647037-99-8 CAPLUS  
CN Furo[2,3-c]indeno[1,2-b]furan-3-carboxamide, N-(4-acetylphenyl)-2-(3,4-dichlorophenyl)-2,3,3a,4,5a,10-hexahydro-5a-hydroxy-4,10-dioxo-, (2R,3S,3aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



REFERENCE COUNT: 22 THERE ARE 22 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2003:59117 CAPLUS  
DOCUMENT NUMBER: 138:119829  
TITLE: Human papillomavirus E2 transactivation domain/inhibitor co-crystal and x-ray coordinates defining the inhibitor-binding pocket  
INVENTOR(S): Cameron, Dale R.; Archambault, Jacques; Yoakim, Christiane; White, Peter  
PATENT ASSIGNEE(S): Boehringer Ingelheim International G.m.b.H., Germany; Wang, Yong  
SOURCE: PCT Int. Appl., 83 pp.  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003006495	A2	20030123	WO 2002-CA1058	20020712
WO 2003006495	A3	20030731		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZH, ZW				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2003082769	A1	20030501	US 2002-193460	20020711
CA 2448482	AA	20030123	CA 2002-2448482	20020712
EP 1409525	A2	20040421	EP 2002-745024	20020712
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, HK, CY, AL, TR, BG, CZ, EE, SK				
JP 2005512954	T2	20050512	JP 2003-512265	20020712
PRIORITY APPLN. INFO.: US 2001-304412P F 20010712 WO 2002-CA1058 W 20020712				

AB A crystallizable composition, comprising an PV E2 TAD-like polypeptide complexed with an inhibitor L is claimed. The invention also provides a method for producing the crystallized HPV E2 TAD-inhibitor complex (HPV E2 TAD-L) comprising: a) mixing purified HPV E2 TAD, contained in a purification buffer, with solubilized inhibitor L to generate a complex solution containing: the HPV E2 TAD-L complex and b) crystallizing the complex from a) in a crystallization buffer. The invention also provides a method for producing crystallized apo HPV E2 TAD, comprising: a) mixing apo HPV E2 TAD, contained in a purification buffer, with a crystallization buffer. X-ray crystal structure coordinates of the HPV E2 TAD-L complex are also provided, which define an inhibitor binding pocket. The inhibitor binding pocket is useful for screening potential small mol. inhibitors that bind to the pocket.


IT 487060-68-4P  
RL: BUU (Biological use, unclassified); PUR (Purification or recovery); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)

L4 ANSWER 4 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

L4 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)  
[human papillomavirus E2 transactivation domain/inhibitor co-crystal and x-ray coordinates defining the inhibitor-binding pocket]


RN 487060-68-4 CAPLUS  
CN Spiro[furan-2(3H),2'-[2H]indene]-3-carboxylic acid, 5-(3,4-dichlorophenyl)-1',3',4,5-tetrahydro-5'-methyl-1',3'-dioxo-4-[[[4-(1,2,3-thiadiazol-4-yl)phenyl]amino]carbonyl]-, monosodium salt, (2'R,3R,4S,5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 487060-71-9P  
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(synthesis of human papillomavirus E2 protein transactivation domain inhibitor)

RN 487060-71-9 CAPLUS  
CN Spiro[furan-2(3H),2'-[2H]indene]-3-carboxylic acid, 5-(3,4-dichlorophenyl)-1',3',4,5-tetrahydro-5'-methyl-1',3'-dioxo-4-[[[4-(1,2,3-thiadiazol-4-yl)phenyl]amino]carbonyl]-, monosodium salt (9CI) (CA INDEX NAME)



● Na



10772721

08/05/05


L4 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

L4 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2002:487569 CAPLUS  
DOCUMENT NUMBER: 137:63181  
TITLE: Preparation of spiroheterocycles for therapeutic use as papilloma virus inhibitors  
INVENTOR(S): Yoakim, Christiane; Hache, Bruno; Ogilvie, William W.; O'Meara, Jeffrey; White, Peter; Goudreau, Nathalie  
PATENT ASSIGNEE(S): Boehringer Ingelheim (Canada) Ltd., Can.  
SOURCE: PCT Int. Appl., 121 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002050082	A2	20020627	WO 2001-CA1800	20011214
WO 2002050082	A3	20021219		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, HL, HR, NE, SN, TD, TG				
CA 2430909	AA	20020627	CA 2001-2430909	20011214
AU 2002018897	A5	20020701	AU 2002-18897	20011214
EP 1345943	A2	20030924	EP 2001-271377	20011214
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2004515555	T2	20040527	JP 2002-551975	20011214
US 2003064985	A1	20030403	US 2001-23975	20011217
US 6759409	B2	20040706		
US 200509855	A1	20050113	US 2004-772721	20040204
PRIORITY APPL. INFO.:				US 2000-256706P F 20001218
				WO 2001-CA1800 W 20011214
				US 2001-23975 A3 20011217
OTHER SOURCE(S): MARPAT 137:63181				
GI				

L4 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




AB Spiroheterocycles, such as I (R1 = H, Me, F, etc.; R3 = alkyl, cycloalkyl, alkylene, aryl, etc.; R4 = carboxylic acid, salt or ester; X = H, W = OH; XW = O, OCH2; Y = Ph, aryl, heteroaryl), were prepared for pharmaceutical use in the treatment or prevention of human papilloma virus infection. Thus, "cis/cis"-spiroheterocycle II was prepared via a multistep synthetic sequence starting from indan-1,3-dione, 3,4-dichlorobenzaldehyde, and 1-(1,3-benzodioxol-5-yl)-1H-pyrrole-2,5-dione. The prepared spiroheterocycles were assayed for E2-dependent E1 DNA binding, SV40 T antigen-DNA binding, and cell-based DNA replication.

IT 439122-77-7P 439122-78-8P 439122-79-9P  
439122-80-2P 439122-81-3P 439122-83-5P  
439122-84-6P 439122-86-8P 439122-87-9P  
439122-89-1P 439122-96-0P 439123-00-9P  
439123-02-1P 439123-03-2P 439123-07-6P  
439123-08-7P 439123-09-8P 439123-10-1P  
439123-13-4P 439123-26-9P 439123-29-2P  
439123-30-5P 439123-31-6P 439123-32-7P  
439123-33-8P 439123-34-9P 439123-38-3P  
439123-44-1P 439123-45-2P 439123-47-4P  
439123-49-6P 439123-51-0P 439123-53-2P  
439123-55-4P 439123-57-6P 439123-60-1P  
439123-62-3P 439123-63-4P 439123-65-6P  
439123-67-8P 439123-68-9P 439123-70-3P  
439123-72-5P 439123-74-7P 439123-75-8P  
439123-76-9P 439123-78-1P 439123-79-2P  
439123-80-5P 439123-82-7P 439123-83-8P  
439123-84-9P 439123-88-3P 439123-89-4P  
439123-90-7P 439123-91-8P 439123-92-5P  
439123-93-0P 439123-94-1P 439123-95-2P  
439123-96-3P 439123-97-4P 439123-98-5P  
439124-00-2P 439124-02-4P 439124-04-6P  
439124-05-7P 439124-06-8P 439124-07-9P  
439124-08-0P 439124-10-4P 439124-12-6P  
439124-14-8P 439124-16-0P 439124-18-2P  
439124-21-7P 439124-23-9P 439124-25-1P  
439124-31-9P 439124-33-1P 439124-35-3P  
439124-39-7P 439124-45-5P 439124-47-7P  
439124-49-9P 439124-51-3P 439124-53-5P  
439124-54-6P 439124-56-8P 439124-57-9P

L4 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

439124-58-0P 439124-59-1P 439124-60-4P  
439124-61-5P 439124-62-6P 439124-63-7P  
439124-64-8P 439124-67-1P 439125-18-5P  
439125-24-3P 439125-30-1P 439125-32-3P  
439125-37-8P 439125-39-0P 439125-47-0P  
439125-49-2P 439125-51-6P 439125-53-8P  
439125-55-0P 439125-57-2P 439125-59-4P  
439125-61-8P 439125-63-0P 439125-71-0P  
RI: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(prepn. of spiroheterocycles for therapeutic use as papilloma virus inhibitors)  
RN 439122-77-7 CAPLUS  
CN Spiro[furan-2(3H),2'-(2H)indene]-3-carboxylic acid, 5-(4-chlorophenyl)-4-[[[4-fluorophenyl]amino]carbonyl]-1',3',4,5-tetrahydro-1',3'-dioxo-, monosodium salt, (3R,4S,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● Na  
RN 439122-78-8 CAPLUS  
CN Spiro[furan-2(3H),2'-(2H)indene]-3-carboxylic acid, 5-(4-chlorophenyl)-4-[[[3,4-dimethoxyphenyl]amino]carbonyl]-1',3',4,5-tetrahydro-1',3'-dioxo-, monosodium salt, (3R,4S,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

10772721


08/05/05

L4 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 439122-79-9 CAPLUS  
 CN Spiro[furan-2(3H),2'-(2H)indene]-3-carboxylic acid, 4-[[4-(4-acetylphenyl)amino]carbonyl]-5-(4-chlorophenyl)-1',3',4,5-tetrahydro-1',3'-dioxo-, monosodium salt, (3R,4S,5R)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



● Na

RN 439122-80-2 CAPLUS  
 CN Spiro[furan-2(3H),2'-(2H)indene]-3-carboxylic acid, 5-(4-chlorophenyl)-4-[[3-(4-chlorophenyl)amino]carbonyl]-1',3',4,5-tetrahydro-1',3'-dioxo-, monosodium salt, (3R,4S,5R)-rel- (9CI) (CA INDEX NAME)


L4 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



● Na

RN 439122-83-5 CAPLUS  
 CN Spiro[furan-2(3H),2'-(2H)indene]-3-carboxylic acid, 5-(4-chlorophenyl)-4-[[2,4-difluorophenyl]amino]carbonyl]-1',3',4,5-tetrahydro-1',3'-dioxo-, monosodium salt, (3R,4S,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● Na

RN 439122-84-6 CAPLUS  
 CN Spiro[furan-2(3H),2'-(2H)indene]-3-carboxylic acid, 5-(4-chlorophenyl)-4-[[4-(4-chlorophenyl)amino]carbonyl]-1',3',4,5-tetrahydro-1',3'-dioxo-, monosodium salt, (3R,4S,5R)-rel- (9CI) (CA INDEX NAME)

L4 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

Relative stereochemistry.




● Na

RN 439122-81-3 CAPLUS  
 CN Spiro[furan-2(3H),2'-(2H)indene]-3-carboxylic acid, 5-(4-chlorophenyl)-1',3',4,5-tetrahydro-4-[[4-(4-methylphenyl)amino]carbonyl]-1',3'-dioxo-, monosodium salt, (3R,4S,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.


L4 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



● Na

RN 439122-86-8 CAPLUS  
 CN Spiro[furan-2(3H),2'-(2H)indene]-3-carboxylic acid, 5-(4-chlorophenyl)-1',3',4,5-tetrahydro-4-[[4-(4-methylphenyl)amino]carbonyl]-1',3'-dioxo-, monosodium salt, (3R,4S,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● Na


RN 439122-87-9 CAPLUS  
 CN Spiro[furan-2(3H),2'-(2H)indene]-3-carboxylic acid, 5-(4-chlorophenyl)-1',3',4,5-tetrahydro-4-[[4-(4-methylphenyl)amino]carbonyl]-1',3'-dioxo-, monosodium salt, (3R,4S,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

10772721


08/05/05

L4 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 439122-89-1 CAPLUS  
 CN Spiro[furan-2(3H), 2'-(2H)indene]-3-carboxylic acid, 5-(4-chlorophenyl)-1',3',4,5-tetrahydro-1',3'-dioxo-4-[[[4-(4-methylphenyl)amino]carbonyl]-1',3',4,5-tetrahydro-1',3'-dioxo-, monosodium salt, (3R,4S,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 439122-96-0 CAPLUS

L4 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 439123-02-1 CAPLUS  
 CN Spiro[furan-2(3H), 2'-(2H)indene]-3-carboxylic acid, 4-[[[4-(4-acetylphenyl)amino]carbonyl]-5-(3,4-dibromophenyl)-1',3',4,5-tetrahydro-1',3'-dioxo-, monosodium salt, (3R,4S,5R)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 439123-03-2 CAPLUS  
 CN Spiro[furan-2(3H), 2'-(2H)indene]-3-carboxylic acid, 5-(3,4-dichlorophenyl)-1',3',4,5-tetrahydro-4-[[[4-(6-methyl-2-benzothiazolyl)phenyl]amino]carbonyl]-1',3'-dioxo-, monosodium salt, (3R,4S,5R)-rel- (9CI) (CA INDEX NAME)

L4 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)  
 CN Spiro[furan-2(3H), 2'-(2H)indene]-3-carboxylic acid, 4-[[[4-(4-acetylphenyl)amino]carbonyl]-5-(3,4-dichlorophenyl)-1',3',4,5-tetrahydro-1',3'-dioxo-, monosodium salt, (3R,4S,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 439123-00-9 CAPLUS  
 CN Spiro[furan-2(3H), 2'-(2H)indene]-3-carboxylic acid, 5-(3,4-dichlorophenyl)-4-[[[4-(1,1-dimethylethyl)phenyl]amino]carbonyl]-1',3',4,5-tetrahydro-1',3'-dioxo-, monosodium salt, (3R,4S,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

L4 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

Relative stereochemistry.

PAGE 1-A




PAGE 2-A

RN 439123-07-6 CAPLUS  
 CN Spiro[furan-2(3H), 2'-(2H)indene]-3-carboxylic acid, 4-[[[4-(4-acetylphenyl)amino]carbonyl]-5-(3-chlorophenyl)-1',3',4,5-tetrahydro-1',3'-dioxo-, monosodium salt, (3R,4S,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.


L4 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



● Na

RN 439123-08-7 CAPLUS  
 CN Spiro[furan-2(3H),2'-(2H)indene]-3-carboxylic acid, 5-(3,4-dichlorophenyl)-1',3',4,5-tetrahydro-4-[[[4-(methylthio)phenyl]amino]carbonyl]-1',3'-dioxo-, monosodium salt, (3R,4S,5R)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



● Na

RN 439123-09-8 CAPLUS  
 CN Spiro[furan-2(3H),2'-(2H)indene]-3-carboxylic acid, 5-(3,4-dichlorophenyl)-1',3',4,5-tetrahydro-4-[[[4-(4-morpholinyl)phenyl]amino]carbonyl]-1',3'-dioxo-, monosodium salt, (3R,4S,5R)-rel- (9CI) (CA INDEX NAME)


L4 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



● Na

RN 439123-13-4 CAPLUS  
 CN Spiro[furan-2(3H),2'-(2H)indene]-3-carboxylic acid, 5-(3,4-dichlorophenyl)-1',3',4,5-tetrahydro-4-[[[4-(1,1-dimethylethoxy)phenyl]amino]carbonyl]-1',3'-dioxo-, monosodium salt, (3R,4S,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● Na

RN 439123-26-9 CAPLUS  
 CN Spiro[furan-2(3H),2'-(2H)indene]-3-carboxylic acid, 5-(3,4-dichlorophenyl)-1',3',4,5-tetrahydro-4-[[[4-(phenoxymethyl)phenyl]amino]carbonyl]-1',3'-dioxo-, monosodium salt, (3R,4S,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

L4 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

Relative stereochemistry.




● Na

RN 439123-10-1 CAPLUS  
 CN Spiro[furan-2(3H),2'-(2H)indene]-3-carboxylic acid, 4-[[[4-(acetamido)phenyl]amino]carbonyl]-5-(3,4-dichlorophenyl)-1',3',4,5-tetrahydro-1',3'-dioxo-, monosodium salt, (3R,4S,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.


L4 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



● Na

RN 439123-29-2 CAPLUS  
 CN Spiro[furan-2(3H),2'-(2H)indene]-3-carboxylic acid, 5-(3,4-dichlorophenyl)-1',3',4,5-tetrahydro-4-[[[4-(1,2,3-thiadiazol-4-yl)phenyl]amino]carbonyl]-1',3'-dioxo-, monosodium salt, (3R,4S,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● Na

RN 439123-30-5 CAPLUS  
 CN Spiro[furan-2(3H),2'-(2H)indene]-3-carboxylic acid, 5-(3,4-dichlorophenyl)-1',3',4,5-tetrahydro-4-[[[4-(methylsulfonyl)phenyl]amino]carbonyl]-1',3'-dioxo-, monosodium salt, (3R,4S,5R)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.

L4 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 439123-31-6 CAPLUS  
 CN Spiro[furan-2(3H),2'-(2H)indene]-3-carboxylic acid, 4-[[[4-(3,4-dichlorophenyl)amino]carbonyl]-5-(3,4-dichlorophenyl)-1',3',4,5-tetrahydro-1',3'-dioxo-, monosodium salt, (3R,4S,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 439123-32-7 CAPLUS  
 CN Spiro[furan-2(3H),2'-(2H)indene]-3-carboxylic acid, 5-(3,4-dichlorophenyl)-4-[[[4-(4-ethylphenyl)amino]carbonyl]-1',3',4,5-tetrahydro-1',3'-dioxo-, monosodium salt, (3R,4S,5R)-rel- (9CI) (CA INDEX NAME)

L4 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)


RN 439123-34-9 CAPLUS  
 CN Spiro[furan-2(3H),2'-(2H)indene]-3-carboxylic acid, 4-[[[4-(benzoylamino)phenyl]amino]carbonyl]-5-(3,4-dichlorophenyl)-1',3',4,5-tetrahydro-1',3'-dioxo-, monosodium salt, (3R,4S,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 439123-38-3 CAPLUS  
 CN Spiro[furan-2(3H),2'-(2H)indene]-3-carboxylic acid, 5-(3,4-difluorophenyl)-1',3',4,5-tetrahydro-4-[[[4-(4-morpholinyl)phenyl]amino]carbonyl]-1',3'-dioxo-, monosodium salt, (3R,4S,5R)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 439123-44-1 CAPLUS


L4 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

Relative stereochemistry.



RN 439123-33-8 CAPLUS  
 CN Spiro[furan-2(3H),2'-(2H)indene]-3-carboxylic acid, 4-[[[4-(4-ethylphenyl)amino]carbonyl]-5-(3,4-dimethylphenyl)-1',3',4,5-tetrahydro-1',3'-dioxo-, monosodium salt, (3R,4S,5R)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



L4 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)


RN 439123-45-2 CAPLUS  
 CN Spiro[furan-2(3H),2'-(2H)indene]-3-carboxylic acid, 4-[[[4-(4-chlorophenyl)amino]carbonyl]-5-(3,4-difluorophenyl)-1',3',4,5-tetrahydro-1',3'-dioxo-, monosodium salt, (3R,4S,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 439123-45-2 CAPLUS  
 CN Spiro[furan-2(3H),2'-(2H)indene]-3-carboxylic acid, 4-[[[4-(4-chlorophenyl)amino]carbonyl]-5-(3,4-difluorophenyl)-1',3',4,5-tetrahydro-1',3'-dioxo-, monosodium salt, (3R,4S,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




10772721

08/05/05

L4 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)  
 RN 439123-47-4 CAPLUS  
 CN Spiro[furan-2(3H),2'-(2H)indene]-3-carboxylic acid, 4-[[4-(4-acetylphenyl)amino]carbonyl]-5-(3,4-difluorophenyl)-1',3',4,5-tetrahydro-1',3'-dioxo-, monosodium salt, (3R,4S,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● Na

RN 439123-49-6 CAPLUS  
 CN Spiro[furan-2(3H),2'-(2H)indene]-3-carboxylic acid, 5-(3,4-dichlorophenyl)-1',3',4,5-tetrahydro-4-[[4-(4-methylphenyl)amino]carbonyl]-1',3'-dioxo-, monosodium salt, (3R,4S,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.


L4 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



● Na

RN 439123-51-0 CAPLUS  
 CN Spiro[furan-2(3H),2'-(2H)indene]-3-carboxylic acid, 4-[[4-(4-acetylphenyl)amino]carbonyl]-5-(3-fluoro-4-(trifluoromethyl)phenyl)-1',3',4,5-tetrahydro-1',3'-dioxo-, monosodium salt, (3R,4S,5R)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



● Na

L4 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)  
 RN 439123-53-2 CAPLUS  
 CN Spiro[furan-2(3H),2'-(2H)indene]-3-carboxylic acid, 5-(3,4-difluorophenyl)-1',3',4,5-tetrahydro-1',3'-dioxo-4-[(phenylamino)carbonyl]-, monosodium salt, (3R,4S,5R)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



● Na

RN 439123-55-4 CAPLUS  
 CN Spiro[furan-2(3H),2'-(2H)indene]-3-carboxylic acid, 4-[[4-(4-acetylphenyl)amino]carbonyl]-5-bromo-5-(3,4-dichlorophenyl)-1',3',4,5-tetrahydro-1',3'-dioxo-, monosodium salt, (2'R,3S,4R,5S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● Na

RN 439123-57-6 CAPLUS  
 CN Spiro[furan-2(3H),2'-(2H)indene]-3-carboxylic acid, 4-[[4-(4-cyanophenyl)amino]carbonyl]-5-(3,4-dichlorophenyl)-1',3',4,5-tetrahydro-1',3'-dioxo-, monosodium salt, (3R,4S,5R)-rel- (9CI) (CA INDEX NAME)

L4 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)


Relative stereochemistry.



● Na

RN 439123-60-1 CAPLUS  
 CN Spiro[furan-2(3H),2'-(2H)indene]-3-carboxylic acid, 5-(3,4-dibromophenyl)-1',3',4,5-tetrahydro-4-[[4-(4-methylphenyl)amino]carbonyl]-1',3'-dioxo-, monosodium salt, (3R,4S,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● Na

RN 439123-62-3 CAPLUS  
 CN Spiro[furan-2(3H),2'-(2H)indene]-3-carboxylic acid, 5-(3,4-difluorophenyl)-1',3',4,5-tetrahydro-4-[[4-(4-methylthio)phenyl]amino]carbonyl]-1',3'-dioxo-

L4 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)  
 , monosodium salt, (3R,4S,5R)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



● Na

RN 439123-63-4 CAPLUS  
 CN Spiro[furan-2(3H), 2'-(2H)indene]-3-carboxylic acid, 5-(3,4-dibromophenyl)-1',3',4,5-tetrahydro-1',3'-dioxo-4-[(phenylamino)carbonyl]-, monosodium salt, (3R,4S,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● Na

RN 439123-65-6 CAPLUS  
 CN Spiro[furan-2(3H), 2'-(2H)indene]-3-carboxylic acid, 5-(3,4-dibromophenyl)-1',3',4,5-tetrahydro-4-[[[4-(1,2,3-thiadiazol-4-yl)phenyl]amino]carbonyl]-, monosodium salt, (3R,4S,5R)-rel- (9CI) (CA INDEX NAME)

L4 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)  
 CN Spiro[furan-2(3H), 2'-(2H)indene]-3-carboxylic acid, 5-(3,4-dibromophenyl)-4-[[[4-(1,1-dimethylethyl)phenyl]amino]carbonyl]-1',3',4,5-tetrahydro-1',3'-dioxo-, monosodium salt, (3R,4S,5R)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



● Na

RN 439123-70-3 CAPLUS  
 CN Spiro[furan-2(3H), 2'-(2H)indene]-3-carboxylic acid, 5-(3,4-dibromophenyl)-1',3',4,5-tetrahydro-4-[[[4-(methylthio)phenyl]amino]carbonyl]-1',3'-dioxo-, monosodium salt, (3R,4S,5R)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



● Na

L4 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)  
 INDEX NAME)


Relative stereochemistry.



● Na

RN 439123-67-8 CAPLUS  
 CN Spiro[furan-2(3H), 2'-(2H)indene]-3-carboxylic acid, 5-(3,4-dibromophenyl)-1',3',4,5-tetrahydro-4-[[[4-(4-morpholinyl)phenyl]amino]carbonyl]-1',3'-dioxo-, monosodium salt, (3R,4S,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● Na

RN 439123-68-9 CAPLUS

L4 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

RN 439123-72-5 CAPLUS  
 CN Spiro[furan-2(3H), 2'-(2H)indene]-3-carboxylic acid, 5-(3,4-difluorophenyl)-1',3',4,5-tetrahydro-4-[[[4-(1,2,3-thiadiazol-4-yl)phenyl]amino]carbonyl]-, monosodium salt, (3R,4S,5R)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



● Na

RN 439123-74-7 CAPLUS  
 CN Spiro[furan-2(3H), 2'-(2H)indene]-3-carboxylic acid, 5-(3-cyanophenyl)-1',3',4,5-tetrahydro-4-[[[4-(4-morpholinyl)phenyl]amino]carbonyl]-1',3'-dioxo-, monosodium salt, (3R,4S,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● Na

RN 439123-75-8 CAPLUS  
 CN Spiro[furan-2(3H), 2'-(2H)indene]-3-carboxylic acid, 5-(3,4-dibromophenyl)-1',3',4,5-tetrahydro-4-[[[4-(methylsulfonyl)phenyl]amino]carbonyl]-1',3'-


L4 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)  
dioxo-, monosodium salt, (3R,4S,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 439123-76-9 CAPLUS  
CN Spiro[furan-2(3H),2'-(2H)indene]-3-carboxylic acid, 4-[[4-(4-acetylphenyl)amino]carbonyl]-1',3',4,5-tetrahydro-5-(2-methyl-5-benzofuranyl)-1',3'-dioxo-, monosodium salt, (3R,4S,5R)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 439123-78-1 CAPLUS  
CN Spiro[2H-benz[f]indene-2,2'-(3'H)-furan]-3'-carboxylic acid, 4'-[[4-(4-acetylphenyl)amino]carbonyl]-5'-(3,4-dichlorophenyl)-1,3,4',5'-tetrahydro-1,3-dioxo-, monosodium salt, (3'R,4'S,5'R)-rel- (9CI) (CA INDEX NAME)


L4 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

Relative stereochemistry.




RN 439123-82-7 CAPLUS  
CN Spiro[furan-2(3H),2'-(2H)indene]-3-carboxylic acid, 4-[[4-(4-acetylphenyl)amino]carbonyl]-5-(3-chloro-4-fluorophenyl)-1',3',4,5-tetrahydro-1',3'-dioxo-, monosodium salt, (3R,4S,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 439123-83-8 CAPLUS  
CN Spiro[2H-benz[e]indene-2,2'-(3'H)-furan]-3'-carboxylic acid,

L4 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)  
Relative stereochemistry.




RN 439123-79-2 CAPLUS  
CN Spiro[2H-benz[e]indene-2,2'-(3'H)-furan]-3'-carboxylic acid, 4'-[[4-(4-acetylphenyl)amino]carbonyl]-5'-(3,4-dichlorophenyl)-1,3,4',5'-tetrahydro-1,3-dioxo-, monosodium salt, (2R,3'S,4'R,5'S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 439123-80-5 CAPLUS  
CN Spiro[furan-2(3H),2'-(2H)indene]-3-carboxylic acid, 4-[[4-(4-acetylphenyl)amino]carbonyl]-5-(3,4-dibromophenyl)-1',3',4,5-tetrahydro-1',3'-dioxo-, monosodium salt, (3R,4S,5R)-rel- (9CI) (CA INDEX NAME)

L4 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)  
Relative stereochemistry.



RN 439123-84-9 CAPLUS  
CN Spiro[furan-2(3H),2'-(2H)indene]-3-carboxylic acid, 5-(3,4-dichlorophenyl)-4-[[4-(3,5-difluorophenyl)amino]carbonyl]-1',3',4,5-tetrahydro-1',3'-dioxo-, monosodium salt, (3R,4S,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 439123-88-3 CAPLUS  
CN Spiro[furan-2(3H),2'-(2H)indene]-3-carboxylic acid, 4-[[4-(3-benzoylphenyl)amino]carbonyl]-5-(3,4-dichlorophenyl)-1',3',4,5-tetrahydro-1',3'-dioxo-, monosodium salt, (3R,4S,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




L4 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



● Na

RN 439123-89-4 CAPLUS  
 CN Spiro[furan-2(3H), 2'-(2H)indene]-3-carboxylic acid, 4-[[[4-bromo-3-chlorophenyl]amino]carbonyl]-5-(3,4-dibromophenyl)-1',3',4,5-tetrahydro-1',3'-dioxo-, monosodium salt, (3R,4S,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● Na

RN 439123-90-7 CAPLUS  
 CN Spiro[furan-2(3H), 2'-(2H)indene]-3-carboxylic acid, 4-[[[3-benzoylphenyl]amino]carbonyl]-5-(3,4-dibromophenyl)-1',3',4,5-tetrahydro-1',3'-dioxo-, monosodium salt, (3R,4S,5R)-rel- (9CI) (CA INDEX NAME)

L4 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

RN 439123-92-9 CAPLUS  
 CN Spiro[furan-2(3H), 2'-(2H)indene]-3-carboxylic acid, 5-(3,4-dibromophenyl)-4-[[[3,4-difluorophenyl]amino]carbonyl]-1',3',4,5-tetrahydro-1',3'-dioxo-, monosodium salt, (3R,4S,5R)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



● Na

RN 439123-93-0 CAPLUS  
 CN Spiro[furan-2(3H), 2'-(2H)indene]-3-carboxylic acid, 4-[[[4-acetylphenyl]amino]carbonyl]-5-(3,4-dichlorophenyl)-5'-fluoro-1',3',4,5-tetrahydro-1',3'-dioxo-, monosodium salt, (2'R,3S,4R,5S)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



● Na

L4 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)  
 1',3'-dioxo-, monosodium salt, (3R,4S,5R)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



● Na

RN 439123-91-8 CAPLUS  
 CN Spiro[furan-2(3H), 2'-(2H)indene]-3-carboxylic acid, 4-[[[4-bromo-3-chlorophenyl]amino]carbonyl]-5-(3,4-dichlorophenyl)-1',3',4,5-tetrahydro-1',3'-dioxo-, monosodium salt, (3R,4S,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● Na

L4 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

RN 439123-94-1 CAPLUS  
 CN Spiro[furan-2(3H), 2'-(2H)indene]-3-carboxylic acid, 4-[[[4-acetylphenyl]amino]carbonyl]-5-(3,4-dichlorophenyl)-5'-fluoro-1',3',4,5-tetrahydro-1',3'-dioxo-, monosodium salt, (2'R,3R,4S,5R)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



● Na

RN 439123-95-2 CAPLUS  
 CN Spiro[furan-2(3H), 2'-(2H)indene]-3-carboxylic acid, 5-(3,4-dibromophenyl)-4-[[[3,5-difluorophenyl]amino]carbonyl]-1',3',4,5-tetrahydro-1',3'-dioxo-, monosodium salt, (3R,4S,5R)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



● Na

L4 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)  
 RN 439123-96-3 CAPLUS  
 CN Spiro[furan-2(3H),2'-[2H]indene]-3-carboxylic acid, 4-[[[4-chlorophenyl]amino]carbonyl]-5-(3,4-dibromophenyl)-1',3',4,5-tetrahydro-1',3'-dioxo-, monosodium salt, (3R,4S,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● Na

RN 439123-97-4 CAPLUS  
 CN Spiro[furan-2(3H),2'-[2H]indene]-3-carboxylic acid, 5-(3,4-dichlorophenyl)-4-[[[3,4-difluorophenyl]amino]carbonyl]-1',3',4,5-tetrahydro-1',3'-dioxo-, monosodium salt, (3R,4S,5R)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



● Na

L4 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)  
 tetrahydro-1',3'-dioxo-, monosodium salt, (2'R,3R,4S,5R)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



● Na


RN 439124-02-4 CAPLUS  
 CN Spiro[furan-2(3H),2'-[2H]indene]-3-carboxylic acid, 4-[[[4-acetylphenyl]amino]carbonyl]-5'-chloro-5-(3,4-dichlorophenyl)-1',3',4,5-tetrahydro-1',3'-dioxo-, monosodium salt, (2'R,3S,4R,5S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● Na

L4 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 439123-98-5 CAPLUS  
 CN Spiro[furan-2(3H),2'-[2H]indene]-3-carboxylic acid, 5-(3,4-dichlorophenyl)-1',3',4,5-tetrahydro-1',3'-dioxo-4-[[[4-(trifluoromethoxy)phenyl]amino]carbonyl]-, monosodium salt, (3R,4S,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● Na

RN 439124-00-2 CAPLUS  
 CN Spiro[furan-2(3H),2'-[2H]indene]-3-carboxylic acid, 4-[[[4-acetylphenyl]amino]carbonyl]-5'-chloro-5-(3,4-dichlorophenyl)-1',3',4,5-

L4 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

RN 439124-04-6 CAPLUS  
 CN Spiro[furan-2(3H),2'-[2H]indene]-3-carboxylic acid, 5-(3,4-dibromophenyl)-1',3',4,5-tetrahydro-1',3'-dioxo-4-[[[4-(trifluoromethoxy)phenyl]amino]carbonyl]-, monosodium salt, (3R,4S,5R)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



● Na

RN 439124-05-7 CAPLUS  
 CN Spiro[furan-2(3H),2'-[2H]indene]-3-carboxylic acid, 4-[[[3-chlorophenyl]amino]carbonyl]-5-(3,4-dibromophenyl)-1',3',4,5-tetrahydro-1',3'-dioxo-, monosodium salt, (3R,4S,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● Na

L4 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

RN 439124-06-8 CAPLUS  
 CN Spiro[furan-2(3H),2'-[2H]indene]-3-carboxylic acid, 5-(3-chloro-4-fluorophenyl)-4-[[[(3,5-difluorophenyl)amino]carbonyl]-1',3',4,5-tetrahydro-1',3'-dioxo-, monosodium salt, (3R,4S,5R)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 439124-07-9 CAPLUS  
 CN Spiro[furan-2(3H),2'-[2H]indene]-3-carboxylic acid, 4-[[[(4-bromo-3-chlorophenyl)amino]carbonyl]-5-(3-chloro-4-fluorophenyl)-1',3',4,5-tetrahydro-1',3'-dioxo-, monosodium salt, (3R,4S,5R)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.

L4 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 439124-08-0 CAPLUS  
 CN Spiro[furan-2(3H),2'-[2H]indene]-3-carboxylic acid, 5-(3-chloro-4-fluorophenyl)-4-[[[(3,4-difluorophenyl)amino]carbonyl]-1',3',4,5-tetrahydro-1',3'-dioxo-, monosodium salt, (3R,4S,5R)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 439124-10-4 CAPLUS  
 CN Spiro[furan-2(3H),2'-[2H]indene]-3-carboxylic acid, 4-[[[(2-chlorophenyl)amino]carbonyl]-5-(3,4-dichlorophenyl)-1',3',4,5-tetrahydro-1',3'-dioxo-, monosodium salt, (3R,4S,5R)-rel- (9CI) (CA INDEX NAME)


L4 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

Relative stereochemistry.



RN 439124-12-6 CAPLUS  
 CN Spiro[furan-2(3H),2'-[2H]indene]-3-carboxylic acid, 5-(3,4-dichlorophenyl)-4-[[[(2-methoxyphenyl)amino]carbonyl]-1',3',4,5-tetrahydro-1',3'-dioxo-, monosodium salt, (3R,4S,5R)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 439124-14-8 CAPLUS  
 CN Spiro[furan-2(3H),2'-[2H]indene]-3-carboxylic acid, 5-(3,4-dichlorophenyl)-4-[[[(2-fluorophenyl)amino]carbonyl]-1',3',4,5-tetrahydro-1',3'-dioxo-, monosodium salt, (3R,4S,5R)-rel- (9CI) (CA INDEX NAME)


L4 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

Relative stereochemistry.



RN 439124-16-0 CAPLUS  
 CN Spiro[furan-2(3H),2'-[2H]indene]-3-carboxylic acid, 5-(3,4-dichlorophenyl)-4-[[[(3,5-dimethylphenyl)amino]carbonyl]-1',3',4,5-tetrahydro-1',3'-dioxo-, monosodium salt, (3R,4S,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 439124-18-2 CAPLUS  
 CN Spiro[furan-2(3H),2'-[2H]indene]-3-carboxylic acid, 4-[[[(3-cyanophenyl)amino]carbonyl]-5-(3,4-dichlorophenyl)-1',3',4,5-tetrahydro-1',3'-dioxo-, monosodium salt, (3R,4S,5R)-rel- (9CI) (CA INDEX NAME)

10772721

08/05/05


L4 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)  
Relative stereochemistry.



● Na


RN 439124-21-7 CAPLUS  
CN Spiro[furan-2(3H),2'-[2H]indene]-3-carboxylic acid, 4-[[4-(4-acetylphenyl)amino]carbonyl]-5-(3,4-dichlorophenyl)-1',3',4,5-tetrahydro-5'-methoxy-1',3'-dioxo-, monosodium salt, (2'R,3R,4S,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● Na


L4 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



● Na

RN 439124-31-9 CAPLUS  
CN Spiro[furan-2(3H),2'-[2H]indene]-3-carboxylic acid, 5-(3,4-difluorophenyl)-1',3',4,5-tetrahydro-4-[[4-(4-methylphenyl)amino]carbonyl]-1',3'-dioxo-, monosodium salt, (3R,4S,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● Na

RN 439124-33-1 CAPLUS  
CN Spiro[furan-2(3H),2'-[2H]indene]-3-carboxylic acid, 5-(3,4-dichlorophenyl)-4-[[2,3-dimethylphenyl]amino]carbonyl]-1',3',4,5-tetrahydro-1',3'-dioxo-, monosodium salt, (3R,4S,5R)-rel- (9CI) (CA INDEX NAME)

L4 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

RN 439124-23-9 CAPLUS  
CN Spiro[furan-2(3H),2'-[2H]indene]-3-carboxylic acid, 4-[[4-(4-acetylphenyl)amino]carbonyl]-5-(3,4-dichlorophenyl)-1',3',4,5-tetrahydro-5'-methoxy-1',3'-dioxo-, monosodium salt, (2'R,3S,4R,5S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● Na

RN 439124-25-1 CAPLUS  
CN Spiro[furan-2(3H),2'-[2H]indene]-3-carboxylic acid, 5-(3-chloro-4-fluorophenyl)-1',3',4,5-tetrahydro-1',3'-dioxo-4-[[4-(trifluoromethoxy)phenyl]amino]carbonyl]-, monosodium salt, (3R,4S,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.


L4 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)  
Relative stereochemistry.



● Na

RN 439124-35-3 CAPLUS  
CN Spiro[furan-2(3H),2'-[2H]indene]-3-carboxylic acid, 5-(3,4-dibromophenyl)-4-[[3,4-dichlorophenyl]amino]carbonyl]-1',3',4,5-tetrahydro-1',3'-dioxo-, monosodium salt, (3R,4S,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● Na

RN 439124-39-7 CAPLUS  
CN Spiro[furan-2(3H),2'-[2H]indene]-3-carboxylic acid, 5-(3,4-dichlorophenyl)-4-[[2-ethoxyphenyl]amino]carbonyl]-1',3',4,5-tetrahydro-1',3'-dioxo-, monosodium salt, (3R,4S,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.


L4 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



● Na

RN 439124-45-5 CAPLUS  
 CN Spiro[furan-2(3H),2'-(2H)indene]-3-carboxylic acid, 5-(3,4-dichlorophenyl)-1',3',4,5-tetrahydro-1',3'-dioxo-4-[[[2-(trifluoromethoxy)phenyl]amino]carbonyl]-, monosodium salt, (3R,4S,5R)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



● Na

RN 439124-47-7 CAPLUS


L4 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



● Na

RN 439124-51-3 CAPLUS  
 CN Spiro[furan-2(3H),2'-(2H)indene]-3-carboxylic acid, 4-[[[4-(4-bromophenyl)amino]carbonyl]-5-(3,5-dichlorophenyl)-1',3',4,5-tetrahydro-1',3'-dioxo-], monosodium salt, (3R,4S,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● Na


RN 439124-53-5 CAPLUS  
 CN Spiro[furan-2(3H),2'-(2H)indene]-3-carboxylic acid, 5-(3,4-dibromophenyl)-1',3',4,5-tetrahydro-1',3'-dioxo-4-[[[4-(4-morpholinyl)phenyl]amino]carbonyl]-, monosodium salt, (2'R,3R,4R,5S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

L4 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)  
 CN Spiro[furan-2(3H),2'-(2H)indene]-3-carboxylic acid, 5-(3,4-dichlorophenyl)-1',3',4,5-tetrahydro-4-[[[4-[[[2-methyl-2-(7-nitro-2,1,3-benzoxadiazol-4-yl)amino]ethyl]amino]-2-oxoethyl]amino]methyl]phenyl]amino]carbonyl]-1',3'-dioxo-, monosodium salt, (3R,4S,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A




● Na

RN 439124-49-9 CAPLUS  
 CN Spiro[furan-2(3H),2'-(2H)indene]-3-carboxylic acid, 4-[[[4-(4-acetylphenyl)amino]carbonyl]-5-(4-chloro-3-[(1-oxopentyl)amino]phenyl)-1',3',4,5-tetrahydro-1',3'-dioxo-], monosodium salt, (3R,4S,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

PAGE 2-A


L4 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



● Na

RN 439124-54-6 CAPLUS  
 CN Spiro[furan-2(3H),2'-(2H)indene]-3-carboxylic acid, 5-(3,4-dibromophenyl)-1',3',4,5-tetrahydro-4-[[[4-(4-morpholinyl)phenyl]amino]carbonyl]-, monosodium salt, (2'R,3R,4S,5R)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



● Na


RN 439124-56-8 CAPLUS  
 CN Spiro[furan-2(3H),2'-(2H)indene]-3-carboxylic acid, 5-(3,4-dichlorophenyl)-1',3',4,5-tetrahydro-5'-methyl-1',3'-dioxo-4-[[[4-(1,2,3-thiadiazol-4-yl)phenyl]amino]carbonyl]-, monosodium salt, (2'R,3S,4R,5S)-rel- (9CI) (CA INDEX NAME)

L4 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)  
Relative stereochemistry.



RN 439124-57-9 CAPLUS  
CN Spiro[furan-2(3H), 2'-(2H)indene]-3-carboxylic acid, 5-(3,4-dichlorophenyl)-1',3',4,5-tetrahydro-5'-methyl-1',3'-dioxo-4-[[[4-(1,2,3-thiadiazol-4-yl)phenyl]amino]carbonyl]-, monosodium salt, (2'R,3R,4S,5R)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 439124-58-0 CAPLUS  
CN Spiro[furan-2(3H), 2'-(2H)indene]-3-carboxylic acid, 5-(3,4-dibromophenyl)-1',3',4,5-tetrahydro-5'-methyl-1',3'-dioxo-4-[[[4-(1,2,3-thiadiazol-4-


L4 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)  
RN 439124-60-4 CAPLUS  
CN Spiro[furan-2(3H), 2'-(2H)indene]-3-carboxylic acid, 5-(3,4-dibromophenyl)-1',3',4,5-tetrahydro-5'-methyl-4-[[[4-(4-morpholinyl)phenyl]amino]carbonyl]-1',3'-dioxo-, monosodium salt, (2'R,3R,4S,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 439124-61-5 CAPLUS  
CN Spiro[furan-2(3H), 2'-(2H)indene]-3-carboxylic acid, 5-(3,4-dibromophenyl)-5'-fluoro-1',3',4,5-tetrahydro-6'-methyl-4-[[[4-(4-morpholinyl)phenyl]amino]carbonyl]-1',3'-dioxo-, monosodium salt, (2'R,3S,4R,5S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




L4 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)  
yl)phenyl]amino]carbonyl]-, monosodium salt, (2'R,3S,4R,5S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 439124-59-1 CAPLUS  
CN Spiro[furan-2(3H), 2'-(2H)indene]-3-carboxylic acid, 5-(3,4-dibromophenyl)-1',3',4,5-tetrahydro-5'-methyl-1',3'-dioxo-4-[[[4-(1,2,3-thiadiazol-4-yl)phenyl]amino]carbonyl]-, monosodium salt, (2'R,3R,4S,5R)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



L4 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)


RN 439124-62-6 CAPLUS  
CN Spiro[furan-2(3H), 2'-(2H)indene]-3-carboxylic acid, 5-(3,4-dibromophenyl)-5'-fluoro-1',3',4,5-tetrahydro-6'-methyl-4-[[[4-(4-morpholinyl)phenyl]amino]carbonyl]-1',3'-dioxo-, monosodium salt, (2'R,3R,4S,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 439124-63-7 CAPLUS  
CN Furo[2,3-c]indeno[1,2-b]furan-3-carboxamide, 2-(3,4-dibromophenyl)-2,3,3a,4,5a,10-hexahydro-5a-hydroxy-8-methyl-N-[4-(4-morpholinyl)phenyl]-4,10-dioxo-, (2R,3S,3aR,5aS,10aR)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 439124-64-8 CAPLUS  
CN Furo[2,3-c]indeno[1,2-b]furan-3-carboxamide, 2-(3,4-dibromophenyl)-


L4 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)  
2,3,3a,4,5a,10-hexahydro-5a-hydroxy-7-methyl-N-[4-(4-morpholinyl)phenyl]-  
4,10-dioxo-, (2R,3S,3aR,5aS,10aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 439124-67-1 CAPLUS  
CN Furo[2,3-c]indeno[1,2-b]furan-3-carboxamide, 2-(3,4-dibromophenyl)-8-fluoro-2,3,3a,4,5a,10-hexahydro-5a-hydroxy-7-methyl-N-[4-(4-morpholinyl)phenyl]-4,10-dioxo-, (2R,3S,3aR,5aS,10aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 439125-18-5 CAPLUS  
CN Furo[2,3-c]indeno[1,2-b]furan-3-carboxamide, N-(2-chlorophenyl)-2-(4-chlorophenyl)-2,3,3a,4,5a,10-hexahydro-5a-hydroxy-4,10-dioxo-, (2R,3S,3aR,5aS,10aR)-rel- (9CI) (CA INDEX NAME)

L4 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 439125-32-3 CAPLUS  
CN Furo[2,3-c]indeno[1,2-b]furan-3-carboxamide, 2-(3,4-dibromophenyl)-2,3,3a,4,5a,10-hexahydro-5a-hydroxy-7-methyl-4,10-dioxo-N-[(1,2,3-thiadiazol-4-yl)phenyl]-, (2R,3S,3aR,5aS,10aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 439125-37-8 CAPLUS  
CN Furo[2,3-c]indeno[1,2-b]furan-3-carboxamide, 2-(3,4-dibromophenyl)-8-fluoro-2,3,3a,4,5a,10-hexahydro-5a-hydroxy-N-[4-(4-morpholinyl)phenyl]-4,10-dioxo-, (2R,3S,3aR,5aS,10aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.


L4 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

Relative stereochemistry.



RN 439125-24-3 CAPLUS  
CN Furo[2,3-c]indeno[1,2-b]furan-3-carboxamide, N-(4-acetylphenyl)-2-(3,4-dichlorophenyl)-2,3,3a,4,5a,10-hexahydro-5a-hydroxy-4,10-dioxo-, (2R,3S,3aR,5aS,10aR)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 439125-30-1 CAPLUS  
CN Furo[2,3-c]indeno[1,2-b]furan-3-carboxamide, N-(4-acetylphenyl)-2-(3-chloro-1H-indol-2-yl)-2,3,3a,4,5a,10-hexahydro-5a-hydroxy-4,10-dioxo-, (2R,3S,3aR,5aS,10aR)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.

L4 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 439125-39-0 CAPLUS  
CN Furo[2,3-c]indeno[1,2-b]furan-3-carboxamide, 2-(3,4-dibromophenyl)-7-fluoro-2,3,3a,4,5a,10-hexahydro-5a-hydroxy-N-[4-(4-morpholinyl)phenyl]-4,10-dioxo-, (2R,3S,3aR,5aS,10aR)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 439125-47-0 CAPLUS  
CN Spiro[furan-2(3H),2'-(2H)indene]-3-carboxylic acid, 4-[[[4-(4-acetylphenyl)amino]carbonyl]-1',3',4,5-tetrahydro-5-(2-naphthalenyl)-1',3'-dioxo-, monosodium salt, (3R,4S,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.


L4 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



● Na

RN 439125-49-2 CAPLUS  
 CN Spiro[furan-2(3H), 2'-(2H)indene]-3-carboxylic acid, 4-[[[4-(4-acetylphenyl)amino]carbonyl]-1',3',4,5-tetrahydro-1',3'-dioxo-5-[(1E)-2-phenylethenyl]-], monosodium salt, (3R,4S,5S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.  
 Double bond geometry as shown.




● Na

RN 439125-51-6 CAPLUS  
 CN Spiro[furan-2(3H), 2'-(2H)indene]-3-carboxylic acid, 4-[[[4-(4-acetylphenyl)amino]carbonyl]-1',3',4,5-tetrahydro-1',3'-dioxo-5-[(1E)-2-(3-bromophenyl)ethenyl]-1',3',4,5-

L4 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

RN 439125-55-0 CAPLUS  
 CN Spiro[furan-2(3H), 2'-(2H)indene]-3-carboxylic acid, 4-[[[4-(4-acetylphenyl)amino]carbonyl]-1',3',4,5-tetrahydro-1',3'-dioxo-5-[(1E)-2-phenyl-1-propenyl]-], monosodium salt, (3R,4S,5S)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.  
 Double bond geometry as shown.



● Na

RN 439125-57-2 CAPLUS  
 CN Spiro[furan-2(3H), 2'-(2H)indene]-3-carboxylic acid, 4-[[[4-(4-acetylphenyl)amino]carbonyl]-1',3',4,5-tetrahydro-5-[(1E)-1-methyl-2-phenylethenyl]-1',3'-dioxo-, monosodium salt, (3R,4S,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.  
 Double bond geometry as shown.




● Na

RN 439125-59-4 CAPLUS

L4 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)  
 tetrahydro-1',3'-dioxo-, monosodium salt, (3R,4S,5S)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.  
 Double bond geometry as shown.



● Na

RN 439125-53-8 CAPLUS  
 CN Spiro[furan-2(3H), 2'-(2H)indene]-3-carboxylic acid, 4-[[[4-(4-acetylphenyl)amino]carbonyl]-5-[(1E)-2-(2-bromophenyl)ethenyl]-1',3',4,5-tetrahydro-1',3'-dioxo-, monosodium salt, (3R,4S,5S)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.  
 Double bond geometry as shown.



● Na

L4 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)  
 CN Spiro[furan-2(3H), 2'-(2H)indene]-3-carboxylic acid, 4-[[[4-(4-acetylphenyl)amino]carbonyl]-5-[(1E)-2-(2,3-dichlorophenyl)ethenyl]-1',3',4,5-tetrahydro-1',3'-dioxo-, monosodium salt, (3R,4S,5S)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.  
 Double bond geometry as shown.



● Na

RN 439125-61-8 CAPLUS  
 CN Spiro[furan-2(3H), 2'-(2H)indene]-3-carboxylic acid, 4-[[[4-(4-acetylphenyl)amino]carbonyl]-1',3',4,5-tetrahydro-5-[(1E)-2-(2-methylphenyl)ethenyl]-1',3'-dioxo-, monosodium salt, (3R,4S,5S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.  
 Double bond geometry as shown.




● Na

RN 439125-63-0 CAPLUS  
 CN Spiro[furan-2(3H), 2'-(2H)indene]-3-carboxylic acid, 4-[[[4-




L4 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)  
 Spiro[furan-2(3H),2'-(2H)indene]-3-carboxylic acid, 5-(3,4-dibromophenyl)-1',3',4,5-tetrahydro-1',3'-dioxo-, monosodium salt, (3R,4S,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.  
 Double bond geometry as shown.



RN 439125-71-0 CAPLUS  
 CN Spiro[furan-2(3H),2'-(2H)indene]-3-carboxylic acid, 5-(3,4-dibromophenyl)-1',3',4,5-tetrahydro-4-[[[4-(4-morpholinyl)phenyl]amino]carbonyl]-1',3'-dioxo-, (3R,4S,5R)-rel- (9CI) (CA INDEX NAME)



Relative stereochemistry.



L4 ANSWER 7 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN  
 ACCESSION NUMBER: 2000:210177 CAPLUS  
 DOCUMENT NUMBER: 132:222527  
 TITLE: Preparation of tetracyclic heterocycles as bactericides and medical fungicides  
 INVENTOR(S): Finn, John; Yu, Xiang Yang; Wang, Zhongguo; Hill, Jason; Keith, Dennis; Gallant, Paul; Wendler, Philip  
 PATENT ASSIGNEE(S): Cubist Pharmaceuticals, Inc., USA  
 SOURCE: PCT Int. Appl., 60 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000017206	A1	20000330	WO 1999-US20930	19990910
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 9958220	A1	20000410	AU 1999-58220	19990910
US 6153645	A	20001128	US 1999-393505	19990910
PRIORITY APPL. INFO.:			US 1998-100809P	P 19980918
			US 1998-102695P	P 19981001
			WO 1999-US20930	W 19990910


OTHER SOURCE(S): MARPAT 132:222527  
 GI



AB Title compds. [I: A = O, S00-2, NR3 OCR4R5, NR3CR4R5, etc.; B = (alkyl)iminocarbonyl or O2C; D = H or (hetero)aryl; M = H, alkyl, aryl, CO2H, etc.; MD = CR:CR(:V), CR:CRCH:CH; E = H, OH, halo, NH2, alkoxy, aryloxy; RR = (un)substituted CH:CHCH:CH, -CH:CHCHN, -CH:CHN:CH, etc.; R1, R2 = (hetero)aryl; R3 = H, alkyl, carboalkoxy (sic), carboxyamido (sic); V, W = O, S, NR13, NR13, NHNR13; X, Y = CH or N; Z = O, NR6, CR7R8, R4-R8, R13 = H or alkyl]. aminoacyl-tRNA synthetase inhibitors, were prepared Thus, 3-phenylspiro[oxirane-2,2'-indan-1',3'-dione] was cyclocondensed with N-(3,4-dichlorophenyl)maleimide (preparation each given) and the product cyclized to give title compound II. Data for biol. activity of I were given.  
 IT 261157-65-7P

L4 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

L4 ANSWER 7 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)  
 RI: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (prepn. of tetracyclic heterocycles as bactericides and medical fungicides)  
 RN 261157-65-7 CAPLUS  
 CN Furo[2,3-c]indeno[1,2-b]furan-3-carboxamide, N-(3,4-dichlorophenyl)-2,3,3a,4,5a,10-hexahydro-4,10-dioxo-2-phenyl- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT